Sygnature Discovery completes acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.. This transaction, following investment from Five Arrows in summer 2021, offers a strategic advantage for both companies, to enable further expansion of the businesses and their capabilities, and forms part of Sygnature’s strategic plan to continuously invest in the expansion of its leading integrated drug discovery solutions.